Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7772804 | 0.89 | PTGS1 (0.36) | PTGS1TPMTALDH1A1MEN1KMT2A | |
| SCHEMBL1039738 | 0.85 | TPMT (0.45) | TPMTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27449011 | 0.83 | TPMT (0.48) | TPMTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27797720 | 0.81 | TPMT (0.42) | TPMTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27383638 | 0.81 | KDM4E (0.43) | TPMTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27797687 | 0.81 | TPMT (0.42) | TPMTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27400020 | 0.81 | TPMT (0.42) | TPMTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3097749 | 0.80 | TPMT (0.56) | TPMTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27567159 | 0.79 | TPMT (0.39) | TPMTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL28013312 | 0.79 | TPMT (0.39) | TPMTALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | claimed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | claimed |
| EP-2225272-B1 | PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS AS (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-8470964-B2 | Peptides derived from NCAM (FGLs) | ENKAM PHARMACEUTICALS A/S (DK) | 2013-06-25 | — | — | US | disclosed |
| EP-1765861-B1 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS AS (DK) | 2012-02-15 | — | — | EP | disclosed |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | COPENHAGEN UNIVERSITY | 2011-04-28 | — | — | US | disclosed |
| EP-2225272-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | Enkam Pharmaceuticals A/S (DK) | 2010-09-08 | — | — | EP | disclosed |
| EP-1660539-B1 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009068042-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
| US-20090105149-A1 | Compounds comprising lpa | ENKAM PHARMACEUTICALS A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090074774-A1 | Fgfr binding peptides | ENKAM PHARMACEUTICALS A/S (DK) | 2009-03-19 | — | — | US | disclosed |
| EP-1765861-A2 | FGFR BINDING PEPTIDES | Enkam Pharmaceuticals A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| EP-1765862-A2 | HEPARIN BINDING PEPTIDE | Enkam Pharmaceuticals A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| EP-1660539-A2 | COMPOUNDS COMPRISING LPA | Enkam Pharmaceuticals A/S (DK) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014623-A9 | COMPOUNDS COMPRISING LPA | — | 2006-03-23 | — | — | WO | disclosed |
| WO-2005123759-A2 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005121168-A2 | HEPARIN BINDING PEPTIDE | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005014623-A2 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | disclosed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105149-A1 | Compounds comprising lpa | FGFR1, FGFR3, FGFR2 | PTGS1 2612/4885TPMT 4443/4885ALDH1A1 3315/4885 |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | L1CAM, FGFR1, FGFR3 | PTGS1 1716/4885TPMT 4724/4885ALDH1A1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.